Celldex Therapeutics Q3 2026 Results: Net Loss of $75.6M, Loss Widens
Celldex Therapeutics reported a net loss of $227.7 million for the first nine months of 2026, driven by increased research and development expenses. The company significantly strengthened its balance sheet through stock issuances, ending the period with $650.3 million in cash, cash equivalents, and marketable securities, which management believes is sufficient to fund operations for at least twelve months.
- Key figure
- Net loss $75.6M